A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma

Published:2015 Issue: Volume: Page:343-357
ISSN:1064-3745
Container-title:Methods in Molecular Biology
language:
Short-container-title:

Author:

Breitbach Caroline J.,Moon Anne,Burke James,Hwang Tae-Ho,Kirn David H.

Publisher

Springer New York

Link

http://link.springer.com/content/pdf/10.1007/978-1-4939-2727-2_19

Reference22 articles.

1. Kirn DH, Thorne SH (2009) Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9(1):64–71. doi: 10.1038/nrc2545

2. Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH (2006) Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 14(3):361–370. doi: 10.1016/j.ymthe.2006.05.008

3. Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC (2011) The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther 20(4):749–758. doi: 10.1038/mt.2011.276

4. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ, Lattime EC (1999) Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6(5):409–422. doi: 10.1038/sj.cgt.7700066

5. Heo J, Breitbach CJ, Moon A, Kim CW, Patt R, Kim MK, Lee YK, Oh SY, Woo HY, Parato K, Rintoul J, Falls T, Hickman T, Rhee BG, Bell JC, Kirn DH, Hwang TH (2011) Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy. Mol Ther 19(6):1170–1179. doi: 10.1038/mt.2011.39

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-Tumor Immunogenicity of the Oncolytic Virus CF33-hNIS-antiPDL1 against Ex Vivo Peritoneal Cells from Gastric Cancer Patients;International Journal of Molecular Sciences;2023-09-16

2. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy;Journal of Translational Medicine;2023-07-25

3. The Clinical Advances of Oncolytic Viruses in Cancer Immunotherapy;Cureus;2023-06-21

4. Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review;Pharmaceutics;2023-06-06

5. Chemo-immunoablation of solid tumors: A new concept in tumor ablation;Frontiers in Immunology;2023-01-12